RELMADA THERAPEUTICS, INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
RELMADA THERAPEUTICS, INC. (RLMD) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$125.75 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2022-03-25
- RELMADA THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2021-12-31 was -$34.38M.
- RELMADA THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2021-09-30 was -$42.61M.
- RELMADA THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2021-06-30 was -$26.55M.
- RELMADA THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2021-03-31 was -$22.22M.
- RELMADA THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2021 was -$125.75M.
- RELMADA THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2020 was -$59.46M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$34.38M derived: 10-K 12 month − 3 quarters · filed 2022-03-25 | -$76.98M derived: sum of 2 quarters · filed 2022-03-25 | -$103.54M derived: sum of 3 quarters · filed 2022-03-25 | -$125.75M 10-K · filed 2022-03-25 |
| 2021-09-30 | -$42.61M 10-Q · filed 2021-11-12 | -$69.16M derived: sum of 2 quarters · filed 2021-11-12 | -$91.37M derived: sum of 3 quarters · filed 2021-11-12 | |
| 2021-06-30 | -$26.55M 10-Q · filed 2021-11-12 | -$48.77M derived: sum of 2 quarters · filed 2021-11-12 | ||
| 2021-03-31 | -$22.22M 10-Q · filed 2021-11-12 | |||
| 2020-12-31 | -$59.46M 10-K · filed 2022-03-25 | |||
| 2020-09-30 | -$16.90M 10-Q · filed 2021-11-12 | -$28.02M derived: sum of 2 quarters · filed 2021-11-12 | -$38.69M derived: sum of 3 quarters · filed 2021-11-12 | |
| 2020-06-30 | -$11.12M 10-Q · filed 2021-11-12 | -$21.79M derived: sum of 2 quarters · filed 2021-11-12 | ||
| 2020-03-31 | -$10.67M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |